Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma

Citation
Ws. Park et al., Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma, J PATHOLOGY, 193(4), 2001, pp. 483-490
Citations number
28
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF PATHOLOGY
ISSN journal
0022-3417 → ACNP
Volume
193
Issue
4
Year of publication
2001
Pages
483 - 490
Database
ISI
SICI code
0022-3417(200104)193:4<483:NLOBIA>2.0.ZU;2-D
Abstract
In this study, mutational and immunohistochemical analyses of beta -catenin were performed in 30 hepatoblastomas, to assess the prevalence of alterati ons of the Wnt pathway with respect to clinicopathological parameters and s urvival. Four missense mutations of beta -catenin (13.3%) were detected and there was strong immunoreactivity for beta -catenin in the cytoplasm and/o r the nucleus in 97% of hepatoblastomas. Nuclear and cytoplasmic staining w as demonstrated in 19 of 30 tumours (63%), while ten revealed only cytoplas mic staining. Statistically, this nuclear beta -catenin staining was signif icantly higher in the embryonal (Fisher exact test; p=0.00393) or undiffere ntiated type (p=0.00156) of hepatoblastoma than in the fetal type, but ther e was no difference between clinical stages I and II and clinical stages II I and IV (p=0.175). Cumulative survival curves showed that nuclear beta -ca tenin staining (generalized Wilcoxon test; p=0.0088), undifferentiated hist ological type (p=0.0305), and clinical stages III and IV (p=0.0107) were si gnificantly correlated with shorter survival time in these patients. Moreov er, Cox multivariate analysis provides evidence that nuclear beta -catenin staining is the most important prognostic factor for survival (p = 0.0090). It is therefore concluded that immunohistochemical analysis of beta -caten in might be a useful clinical tool for estimating the prognosis for patient s with hepatoblastoma. Copyright (C) 2000 John Wiley & Sons, Ltd.